OBJECTIVE: To determine the cognitive effects of long-term dietary soy isoflavones in a daily dose comparable to that of traditional Asian diets. METHODS: In the double-blind Women's Isoflavone Soy Health trial, healthy postmenopausal women were randomly allocated to receive daily 25 g of isoflavone-rich soy protein (91 mg of aglycone weight of isoflavones: 52 mg of genistein, 36 mg of daidzein, and 3 mg glycitein) or milk protein-matched placebo. The primary cognitive endpoint compared between groups at 2.5 years was change from baseline on global cognition, a composite of the weighted sum of 14 neuropsychological test score changes. Secondary outcomes compared changes in cognitive factors and individual tests. RESULTS: A total of 350 healthy postmenopausal women aged 45-92 years enrolled in this trial; 313 women with baseline and endpoint cognitive test data were included in intention-to-treat analyses. Adherence in both groups was nearly 90%. There was no significant between-group difference on change from baseline in global cognition (mean standardized improvement of 0.42 in the isoflavone group and 0.31 in the placebo group; mean standardized difference 0.11, 95% confidence interval [CI] -0.13 to 0.35). Secondary analyses indicated greater improvement on a visual memory factor in the isoflavone group (mean standardized difference 0.33, 95% CI 0.06-0.60) but no significant between-group differences on 3 other cognitive factors or individual test scores, and no significant difference within a subgroup of younger postmenopausal women. CONCLUSION: For healthy postmenopausal women, long-term dietary soy isoflavone supplementation in a dose comparable to that of traditional Asian diets has no effect on global cognition but may improve visual memory. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that long-term dietary supplementation with isoflavone-rich soy protein does not improve global cognition of healthy postmenopausal women.
RCT Entities:
OBJECTIVE: To determine the cognitive effects of long-term dietary soy isoflavones in a daily dose comparable to that of traditional Asian diets. METHODS: In the double-blind Women's Isoflavone Soy Health trial, healthy postmenopausal women were randomly allocated to receive daily 25 g of isoflavone-rich soy protein (91 mg of aglycone weight of isoflavones: 52 mg of genistein, 36 mg of daidzein, and 3 mg glycitein) or milk protein-matched placebo. The primary cognitive endpoint compared between groups at 2.5 years was change from baseline on global cognition, a composite of the weighted sum of 14 neuropsychological test score changes. Secondary outcomes compared changes in cognitive factors and individual tests. RESULTS: A total of 350 healthy postmenopausal women aged 45-92 years enrolled in this trial; 313 women with baseline and endpoint cognitive test data were included in intention-to-treat analyses. Adherence in both groups was nearly 90%. There was no significant between-group difference on change from baseline in global cognition (mean standardized improvement of 0.42 in the isoflavone group and 0.31 in the placebo group; mean standardized difference 0.11, 95% confidence interval [CI] -0.13 to 0.35). Secondary analyses indicated greater improvement on a visual memory factor in the isoflavone group (mean standardized difference 0.33, 95% CI 0.06-0.60) but no significant between-group differences on 3 other cognitive factors or individual test scores, and no significant difference within a subgroup of younger postmenopausal women. CONCLUSION: For healthy postmenopausal women, long-term dietary soy isoflavone supplementation in a dose comparable to that of traditional Asian diets has no effect on global cognition but may improve visual memory. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that long-term dietary supplementation with isoflavone-rich soy protein does not improve global cognition of healthy postmenopausal women.
Authors: L R Fournier; T A Ryan Borchers; L M Robison; M Wiediger; J S Park; B P Chew; M K McGuire; D A Sclar; T L Skaer; K A Beerman Journal: J Nutr Health Aging Date: 2007 Mar-Apr Impact factor: 4.075
Authors: Suzanne C Ho; Agnes S Y Chan; Yee Ping Ho; Edwin K F So; Aprille Sham; Benny Zee; Jean L F Woo Journal: Menopause Date: 2007 May-Jun Impact factor: 2.953
Authors: Heidi D Nelson; Kimberly K Vesco; Elizabeth Haney; Rongwei Fu; Anne Nedrow; Jill Miller; Christina Nicolaidis; Miranda Walker; Linda Humphrey Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Miriam González; Alfredo Cabrera-Socorro; Carlos G Pérez-García; James D Fraser; Francisco J López; Rafael Alonso; Gundela Meyer Journal: J Comp Neurol Date: 2007-08-20 Impact factor: 3.215
Authors: Marguerite A Klein; Richard L Nahin; Mark J Messina; Jeanne I Rader; Lilian U Thompson; Thomas M Badger; Johanna T Dwyer; Young S Kim; Carol H Pontzer; Pamela E Starke-Reed; Connie M Weaver Journal: J Nutr Date: 2010-04-14 Impact factor: 4.798
Authors: Jan A St John; Victor W Henderson; Howard N Hodis; Naoko Kono; Carol A McCleary; Adrian A Franke; Wendy J Mack Journal: J Am Geriatr Soc Date: 2014-03-11 Impact factor: 5.562
Authors: Howard N Hodis; Wendy J Mack; Donna Shoupe; Stanley P Azen; Frank Z Stanczyk; Juliana Hwang-Levine; Matthew J Budoff; Victor W Henderson Journal: Menopause Date: 2015-04 Impact factor: 2.953
Authors: Steven L Neese; Samantha L Pisani; Daniel R Doerge; William G Helferich; Estatira Sepehr; Amar G Chittiboyina; Sateesh Chandra Kumar Rotte; Troy J Smillie; Ikhlas A Khan; Donna L Korol; Susan L Schantz Journal: Neurotoxicol Teratol Date: 2013-12-22 Impact factor: 3.763
Authors: Keiko Kurita; Victor W Henderson; Margaret Gatz; Jan St John; Howard N Hodis; Roksana Karim; Wendy J Mack Journal: Fertil Steril Date: 2016-05-14 Impact factor: 7.329